Duality Advisers’s Myriad Genetics MYGN Stock Holding History

Duality Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,528	Closed	-$454K	–	673
2023 Q1	$454K	Sell	19,528 -33,315	-63%	-$677K	0.05%	424
2022 Q4	$767K	Buy	+52,843	New	+$985K	0.09%	368
2022 Q3	–	Sell	-21,188	Closed	-$385K	–	672
2022 Q2	$385K	Buy	+21,188	New	+$440K	0.04%	498
2022 Q1	–	Sell	-42,740	Closed	-$1.18M	–	765
2021 Q4	$1.18M	Buy	+42,740	New	+$1.24M	0.13%	263
2020 Q4	–	Sell	-97,680	Closed	-$1.27M	–	667
2020 Q3	$1.27M	Sell	97,680 -66,037	-40%	-$836K	0.08%	316
2020 Q2	$1.86M	Buy	+163,717	New	+$2.32M	0.17%	166

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Duality Advisers's MYGN Position: Q2 2023 in Review

Duality Advisers sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 19,528 shares — an estimated $454K sold.

Duality Advisers first reported a position in MYGN in Q2 2020 and held it in 6 quarters. The position peaked at $1.86M in Q2 2020. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Duality Advisers reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Duality Advisers sold 19,528 Myriad Genetics shares in Q2 2023, an estimated $454K.
Duality Advisers first reported a position in Myriad Genetics in Q2 2020 and held it in 6 quarters.
Duality Advisers's Myriad Genetics position peaked at $1.86M in Q2 2020.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Duality Advisers's 13F filing for Q2 2023, filed 31 Jul 2023.